IMMUNOTHERAPY SIDE EFFECTS:
WHAT PATIENTS NEED TO KNOW
Immunotherapy side effects are unlike chemotherapy — they can appear in any organ, at any time, and the correct response is immune suppression, not simply stopping the drug.
analyticsAt a Glance
- check_circleImmune-related adverse events (irAEs) occur in 60–85% of patients on checkpoint inhibitors — most are mild, but 10–15% are severe
- check_circleSkin, bowel, lung, liver, and endocrine glands are the most commonly affected organs
- check_circleEarly recognition — within days of symptom onset — prevents severe, life-threatening toxicity
- check_circleMost irAEs are fully reversible with prompt corticosteroid treatment — permanent checkpoint inhibitor discontinuation is not always required
What Are Immune-Related Adverse Events (irAEs)?
Immune checkpoint inhibitors work by releasing the brakes on the immune system — enabling T cells to attack tumour cells. However, this same mechanism can direct immune activation against normal tissues, causing inflammation in almost any organ. These immune-related adverse events (irAEs) are fundamentally different from chemotherapy toxicity in their mechanism, timing, management, and potential for severe outcome if missed.
“The immune system does not know where the tumour ends and normal tissue begins. The same drug that fights the cancer can turn against any organ in the body.”
Different from Chemotherapy Side Effects
Chemotherapy toxicity (hair loss, nausea, low blood counts) peaks 1–2 weeks after infusion and follows a predictable pattern. irAEs have variable onset — appearing days to over a year after starting therapy — affect different organs in each patient, and are treated with immune suppression rather than dose reduction.
The Timing Problem
irAEs can appear during treatment, weeks after dose reductions, or months after completing immunotherapy. Patients must remain vigilant for irAE symptoms not just during active treatment but for at least 6–12 months after stopping checkpoint inhibitors — any new inflammatory symptom in this period warrants urgent assessment.
irAE Frequency and Severity: Key Numbers
Understanding how common irAEs are — and which require immediate attention — helps patients monitor themselves effectively.
- 60–85%Patients on checkpoint inhibitors who experience at least one irAE of any gradeThe majority of patients on PD-1/PD-L1 inhibitors experience at least a mild irAE. Combination therapy (PD-1 + CTLA-4 blockade, e.g., nivolumab + ipilimumab) has significantly higher irAE rates than monotherapy.
- 10–15%Patients who experience a severe (Grade 3–4) irAE requiring hospitalisation or corticosteroidsSevere irAEs — colitis, pneumonitis, hepatitis, hypophysitis — require immediate corticosteroid treatment. Untreated Grade 3–4 irAEs can be life-threatening.
- 0.3–1.3%Treatment-related mortality from irAEs on checkpoint inhibitor monotherapyDeaths from irAEs, though rare, are most often due to myocarditis (heart inflammation), pneumonitis, or severe colitis — typically in patients who received treatment late or with inadequate immune suppression.
Immune-Related Adverse Events by Organ System
This reference table covers the most common and clinically important irAEs — symptoms to recognise, frequency, and the urgency of reporting.
| Organ System | irAE Name | Symptoms to Report | Frequency | Urgency |
|---|---|---|---|---|
| Skin | Dermatitis / rash | New rash, blistering, skin peeling, mouth sores | 30–40% (any grade) | Report within 24–48 hrs if Grade 2+ |
| Gastrointestinal | Colitis | Diarrhoea >4 stools/day above baseline, blood in stool, abdominal pain | 8–20% (higher with combo) | Same-day report — Grade 3 colitis is a medical emergency |
| Lung | Pneumonitis | New cough, shortness of breath, chest pain, reduced exercise tolerance | 3–5% (higher with combo) | Same-day report — pneumonitis can progress rapidly |
| Liver | Hepatitis | No symptoms in early stages — detected on blood tests; jaundice in severe cases | 5–10% | Weekly LFT monitoring; report jaundice or abdominal pain immediately |
| Endocrine | Thyroid dysfunction (hypo or hyper) | Fatigue, weight changes, heat/cold intolerance, heart palpitations | 6–20% | Report within 1–2 weeks; TSH screening every 6–12 weeks |
| Endocrine | Hypophysitis (pituitary inflammation) | Headache, fatigue, visual disturbance, secondary hormone deficiencies | 1–5% (higher with ipilimumab) | Urgent — can cause adrenal crisis if ACTH deficiency develops |
| Heart | Myocarditis | Chest pain, shortness of breath, palpitations, lower limb oedema, fatigue | 0.5–1% but high mortality | Emergency — call hospital immediately; myocarditis can be fatal within hours |
| Joints/Muscles | Arthritis, myositis | Joint swelling and pain, muscle weakness (especially proximal muscles, difficulty rising from chair) | 2–15% | Report within 1–2 weeks; myositis with elevated CK is high priority |
How irAEs Are Managed: The Grade-Based Response
irAE management is standardised by severity grade (1 = mild; 4 = life-threatening) and follows a consistent protocol of withholding therapy, immune suppression, and specialist referral.
- 1
Grade 1 — Mild Symptoms: Continue Checkpoint Inhibitor with Monitoring
Mild rash, diarrhoea 1–2 stools above baseline, asymptomatic liver enzyme elevation <3× ULN. Continue immunotherapy; increase monitoring frequency; topical treatments where applicable.
- 2
Grade 2 — Moderate Symptoms: Hold Checkpoint Inhibitor
Rash affecting >30% BSA, diarrhoea 4–6 stools above baseline, liver enzymes 3–5× ULN, symptomatic thyroid disease. Hold immunotherapy; start oral prednisolone 0.5–1 mg/kg/day; specialist referral.
- 3
Grade 3 — Severe Symptoms: Hold + High-Dose Corticosteroids
Severe colitis with blood in stool, pneumonitis with significant dyspnoea, hepatitis with enzymes >5× ULN, myocarditis. Hold immunotherapy indefinitely; IV methylprednisolone 1–2 mg/kg/day; hospital admission; specialist review.
- 4
Grade 4 — Life-Threatening: Permanently Discontinue
Life-threatening colitis, myocarditis, pneumonitis, or other organ failure. Permanently discontinue checkpoint inhibitor; high-dose IV corticosteroids and/or additional immunosuppressants (infliximab, mycophenolate, ciclosporin) as indicated by organ affected.
- 5
Resuming Immunotherapy After irAE Resolution
After Grade 1–2 irAEs have resolved to Grade 0–1 and steroids have been tapered over at least 4–6 weeks, immunotherapy may be resumed. After Grade 3 events, resumption requires multidisciplinary discussion. Grade 4 events generally preclude resumption.
Monotherapy vs Combination Immunotherapy: irAE Risk Differences
Combining PD-1/PD-L1 inhibitors with CTLA-4 inhibitors (e.g., nivolumab + ipilimumab) achieves superior tumour responses in some cancers but at the cost of significantly higher irAE rates.
PD-1/PD-L1 Monotherapy
- Any-grade irAE rate: 60–70%Lower overall irAE rate than combination — most are mild Grade 1–2 events manageable without stopping treatment.
- Grade 3–4 irAE rate: 10–15%Severe irAEs occur in a minority of monotherapy patients — colitis, pneumonitis, and hepatitis are the most common serious events.
- Endocrine irAEs common but manageableThyroid dysfunction (hypo- and hyperthyroidism) is the most common endocrine irAE with monotherapy — typically managed with hormone replacement without stopping treatment.
PD-1 + CTLA-4 Combination
- Any-grade irAE rate: 85–95%The vast majority of patients on combination therapy experience at least one irAE — intensive monitoring is mandatory throughout treatment.
- Grade 3–4 irAE rate: 30–55%Severe irAEs affect a substantial proportion of patients on combination therapy — patients must be counselled about this risk and treated at experienced centres with immediate access to specialist management.
- Colitis significantly more common with CTLA-4 inhibitionIpilimumab-based combinations carry particularly elevated colitis risk — Grade 3 colitis occurs in 5–10% vs <2% with PD-1 monotherapy. Prophylactic budesonide is under investigation.
Frequently Asked Questions
Common questions from patients receiving immunotherapy about side effects and management.
About Immunotherapy Side Effects
If I get a severe side effect, does it mean my immunotherapy has to be stopped permanently?
Not necessarily. Grade 1–2 irAEs are usually managed by temporarily holding the checkpoint inhibitor, treating with corticosteroids, and resuming once the irAE has resolved. Even Grade 3 events can sometimes be followed by careful rechallenge after full resolution and steroid taper. Permanent discontinuation is required for Grade 4 events and for certain life-threatening irAEs (myocarditis, severe neurological events). The decision is always made individually in MDT discussion.
Should I take steroids preventatively before starting immunotherapy?
Routine prophylactic corticosteroids are not standard practice and are not recommended — they may reduce immunotherapy efficacy. Prophylactic antibiotics (co-trimoxazole) for Pneumocystis pneumonia are sometimes given when high-dose steroids are used to treat irAEs. Certain centres are studying prophylactic budesonide for colitis prevention in high-risk patients — this is not yet standard.
Can I take herbal medicines or supplements during immunotherapy?
Several herbal products have immune-modulating properties that may interact unpredictably with checkpoint inhibitors — either amplifying irAE risk or interfering with treatment efficacy. St John's Wort, astragalus, cat's claw, and high-dose antioxidants are among the most concerning. Always disclose all supplements to your oncologist before starting immunotherapy.
What should I do if I develop a new symptom between infusions?
Do not wait for your next scheduled appointment. Contact your oncology team on the same day for any: shortness of breath or new cough, bloody or significantly increased diarrhoea, chest pain, severe headache, visual changes, or new significant fatigue. Many cancer centres have 24-hour helplines specifically for patients on active treatment — use them. Early treatment of irAEs prevents severe outcomes.
More from the Supportive Care Resource Library
Continue exploring supportive care and treatment management guides.
- ↑ Supportive Care — Complete Guide
- Cancer Pain Management: A Complete Patient Guide
- Psychological Support in Cancer: A Guide for Patients and Families
- Nutritional Support During Cancer Treatment
- Survivorship After Cancer Treatment: Managing Late Effects
- Bone Metastases: Pain Management and Treatment Options
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Access Specialist Support for Immunotherapy Management
CancerFax connects patients receiving immunotherapy with specialist oncology centres experienced in irAE recognition and management — ensuring toxicity is identified and treated promptly to protect both safety and treatment continuation.
This content is for informational purposes only. All immunotherapy-related symptoms should be reported to your oncology team immediately — do not wait for a scheduled appointment.